




ELSEVIER

Contents lists available at ScienceDirect

Food and Chemical Toxicology

journal homepage: www.elsevier.com/locate/foodchemtox

Short Review

RIFM fragrance ingredient safety assessment, lactoscatone, CAS Registry Number 21280-29-5



A.M. Api^a, D. Belsito^b, D. Botelho^a, M. Bruze^c, G.A. Burton Jr.^d, J. Buschmann^e, M.L. Dagli^f, M. Date^a, W. Dekant^g, C. Deodhar^a, M. Francis^a, A.D. Fryer^h, L. Jones^a, K. Joshi^a, S. La Cava^a, A. Lapczynski^a, D.C. Lieblerⁱ, D. O'Brien^a, A. Patel^a, T.M. Penning^j, G. Ritacco^a, J. Romine^a, N. Sadekar^a, D. Salvito^a, T.W. Schultz^k, I.G. Sipes^l, G. Sullivan^{a,*}, Y. Thakkar^a, Y. Tokura^m, S. Tsang^a

^a Research Institute for Fragrance Materials, Inc., 50 Tice Boulevard, Woodcliff Lake, NJ, 07677, USA

^b Member RIFM Expert Panel, Columbia University Medical Center, Department of Dermatology, 161 Fort Washington Ave., New York, NY, 10032, USA

^c Member RIFM Expert Panel, Malmö University Hospital, Department of Occupational & Environmental Dermatology, Sodra Forstadsgatan 101, Entrance 47, Malmö, SE-20502, Sweden

^d Member RIFM Expert Panel, School of Natural Resources & Environment, University of Michigan, Dana Building G110, 440 Church St., Ann Arbor, MI, 48109, USA

^e Member RIFM Expert Panel, Fraunhofer Institute for Toxicology and Experimental Medicine, Nikolai-Fuchs-Strasse 1, 30625, Hannover, Germany

^f Member RIFM Expert Panel, University of Sao Paulo, School of Veterinary Medicine and Animal Science, Department of Pathology, Av. Prof. dr. Orlando Marques de Paiva, 87, Sao Paulo, CEP 05508-900, Brazil

^g Member RIFM Expert Panel, University of Würzburg, Department of Toxicology, Versbacher Str. 9, 97078, Würzburg, Germany

^h Member RIFM Expert Panel, Oregon Health Science University, 3181 SW Sam Jackson Park Rd., Portland, OR, 97239, USA

ⁱ Member RIFM Expert Panel, Vanderbilt University School of Medicine, Department of Biochemistry, Center in Molecular Toxicology, 638 Robinson Research Building, 2200 Pierce Avenue, Nashville, TN, 37232-0146, USA

^j Member of RIFM Expert Panel, University of Pennsylvania, Perelman School of Medicine, Center of Excellence in Environmental Toxicology, 1316 Biomedical Research Building (BRB) II/III, 421 Curie Boulevard, Philadelphia, PA, 19104-3083, USA

^k Member RIFM Expert Panel, The University of Tennessee, College of Veterinary Medicine, Department of Comparative Medicine, 2407 River Dr., Knoxville, TN, 37996-4500, USA


^l Member RIFM Expert Panel, Department of Pharmacology, University of Arizona, College of Medicine, 1501 North Campbell Avenue, P.O. Box 245050, Tucson, AZ, 85724-5050, USA

^m Member RIFM Expert Panel, The Journal of Dermatological Science (JDS), Editor-in-Chief, Professor and Chairman, Department of Dermatology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, 431-3192, Japan

Version: 110818. This version replaces any previous versions.

Name: Lactoscatone

CAS Registry Number: 21280-29-5

**Abbreviation/Definition List:**

2-Box Model - A RIFM, Inc. proprietary *in silico* tool used to calculate fragrance air exposure concentration

AF - Assessment Factor

BCF - Bioconcentration Factor

Creme RIFM Model - The Creme RIFM Model uses probabilistic (Monte Carlo) simulations to allow full distributions of data sets, providing a more realistic estimate of aggregate exposure to individuals across a population (Comiskey et al., 2015, 2017; Safford et al., 2015a, 2017) compared to a deterministic aggregate approach

DEREK - Derek Nexus is an *in silico* tool used to identify structural alerts

DST - Dermal Sensitization Threshold

ECHA - European Chemicals Agency

EU - Europe/European Union

GLP - Good Laboratory Practice

IFRA - The International Fragrance Association

LOEL - Lowest Observable Effect Level

* Corresponding author.

E-mail address: gsullivan@rifm.org (G. Sullivan).

<https://doi.org/10.1016/j.fct.2019.01.022>

Received 8 November 2018; Accepted 21 January 2019

Available online 29 January 2019

0278-6915/© 2019 Elsevier Ltd. All rights reserved.

MOE - Margin of Exposure
 MPPD - Multiple-Path Particle Dosimetry. An *in silico* model for inhaled vapors used to simulate fragrance lung deposition
 NA - North America
 NESIL - No Expected Sensitization Induction Level
 NOAEC - No Observed Adverse Effect Concentration
 NOAEL - No Observed Adverse Effect Level
 NOEC - No Observed Effect Concentration
 NOEL - No Observed Effect Level
 OECD - Organisation for Economic Co-operation and Development
 OECD TG - Organisation for Economic Co-operation and Development Testing Guidelines
 PBT - Persistent, Bioaccumulative, and Toxic
 PEC/PNEC - Predicted Environmental Concentration/Predicted No Effect Concentration
 QRA - Quantitative Risk Assessment
 REACH - Registration, Evaluation, Authorisation, and Restriction of Chemicals
 RfD - Reference Dose
 RIFM - Research Institute for Fragrance Materials
 RQ - Risk Quotient
Statistically Significant - Statistically significant difference in reported results as compared to controls with a $p < 0.05$ using appropriate statistical test
 TTC - Threshold of Toxicological Concern
 UV/Vis spectra - Ultraviolet/Visible spectra
 VCF - Volatile Compounds in Food
 VoU - Volume of Use vPvB - (very) Persistent, (very) Bioaccumulative
 WoE - Weight of Evidence

The Expert Panel for Fragrance Safety* concludes that this material is safe under the limits described in this safety assessment.

This safety assessment is based on the RIFM Criteria Document (Api et al., 2015), which should be referred to for clarifications. Each endpoint discussed in this safety assessment includes the relevant data that were available at the time of writing (version number in the top box is indicative of the date of approval based on a 2-digit month/day/year), both in the RIFM database (consisting of publicly available and proprietary data) and through publicly available information sources (e.g., SciFinder and PubMed). Studies selected for this safety assessment were based on appropriate test criteria, such as acceptable guidelines, sample size, study duration, route of exposure, relevant animal species, most relevant testing endpoints, etc. A key study for each endpoint was selected based on the most conservative endpoint value (e.g., PNEC, NOAEL, LOEL, and NESIL).

*The Expert Panel for Fragrance Safety is an independent body that selects its own members and establishes its own operating procedures. The Expert Panel is comprised of internationally known scientists that provide RIFM with guidance relevant to human health and environmental protection.

Summary: The use of this material under current conditions is supported by existing information.

Lactoscatone was evaluated for genotoxicity, repeated dose toxicity, reproductive toxicity, local respiratory toxicity, phototoxicity/photoallergenicity, skin sensitization, and environmental safety. Data from read-across analog octahydrocoumarin (CAS # 4430-31-3) show that lactoscatone is not expected to be genotoxic. The skin sensitization endpoint was completed using DST for non-reactive materials ($900 \mu\text{g}/\text{cm}^2$); exposure is below the DST. The repeated dose, reproductive, and local respiratory toxicity endpoints were evaluated using the TTC for a Cramer Class III material, and the exposure to lactoscatone is below the TTC ($0.0015 \text{ mg}/\text{kg}/\text{day}$, $0.0015 \text{ mg}/\text{kg}/\text{day}$, and $0.47 \text{ mg}/\text{day}$, respectively). The phototoxicity/photoallergenicity endpoints were evaluated based on UV spectra; lactoscatone is not expected to be phototoxic/photoallergenic. The environmental endpoints were evaluated; lactoscatone was found not to be PBT as per the IFRA Environmental Standards, and its risk quotients, based on its current volume of use in Europe and North America (i.e., PEC/PNEC), are < 1 .

Human Health Safety Assessment

Genotoxicity: Not expected to be genotoxic.

(RIFM, 2013a; RIFM, 2014)

Repeated Dose Toxicity: No NOAEL available. Exposure is below the TTC.

Reproductive Toxicity: No NOAEL available. Exposure is below the TTC.

Skin Sensitization: No safety concerns at current, declared use levels. Exposure is below the DST.

Phototoxicity/Photoallergenicity: Not expected to be phototoxic/photoallergenic.

(UV Spectra, RIFM Database)

Local Respiratory Toxicity: No NOAEC available. Exposure is below the TTC.

Environmental Safety Assessment

Hazard Assessment:

Persistence: Critical Measured Value: 9.4% (BODIS)

RIFM (1996)

Bioaccumulation: Screening-level: $68.7 \text{ L}/\text{kg}$

(EPI Suite v4.11; US EPA, 2012a)

Ecotoxicity: Screening-level: Fish LC50: $22.62 \text{ mg}/\text{L}$

(RIFM Framework; Salvito et al., 2002)

Conclusion: Not PBT or vPvB as per IFRA Environmental Standards

Risk Assessment:

Screening-level: PEC/PNEC (North America and Europe) < 1

(RIFM Framework; Salvito et al., 2002)

Critical Ecotoxicity Endpoint: Fish LC50: $22.62 \text{ mg}/\text{L}$

(RIFM Framework; Salvito et al., 2002)

RIFM PNEC is: $0.02262 \mu\text{g}/\text{L}$

- Revised PEC/PNECs (2015 IFRA VoU): North America and Europe: not applicable; cleared at screening-level

1. Identification

1. **Chemical Name:** Lactoscatone

2. **CAS Registry Number:** 21280-29-5

3. **Synonyms:** Decahydro-4a-hydroxy-2,8,8-trimethyl-2-naphthoic acid δ -lactone; Decahydro-2,8,8-trimethylnaphthalene-2,4a-carbolactone; 3,8a-Ethano-8aH-1-benzopyran-2(3H)-one, hexahydro-3,5,5-trimethyl-; デカハイドロ - 4 α - ハイドロキシ - 2, 8, 8 - トリメチル - 2 - ナフト工酸ラクトン; 2,8,8-Trimethyloctahydro-2H-4a,2-(epoxymethano)naphthalen-10-one; Lactoscatone

4. **Molecular Formula:** $\text{C}_{14}\text{H}_{22}\text{O}_2$

5. **Molecular Weight:** 222.33

6. **RIFM Number:** 1149

7. **Stereochemistry:** Stereoisomer not specified. Three stereocenters and 8 total stereoisomers possible.

2. Physical data

1. **Boiling Point:** $319.12 \text{ }^\circ\text{C}$ (EPI Suite)

2. **Flash Point:** $> 93 \text{ }^\circ\text{C}$ (GHS), $> 200 \text{ }^\circ\text{F}$; CC (FMA Database)

3. **Log K_{ow} :** 3.29 (EPI Suite)

4. **Melting Point:** $93.27 \text{ }^\circ\text{C}$ (EPI Suite)

5. **Water Solubility:** $51.92 \text{ mg}/\text{L}$ (EPI Suite)

6. **Specific Gravity:** Not Available

7. **Vapor Pressure:** 0.0000788 mm Hg @ $20 \text{ }^\circ\text{C}$ (EPI Suite v4.0), 0.000154 mm Hg @ $25 \text{ }^\circ\text{C}$ (EPI Suite)

8. **UV Spectra:** No significant absorbance between 290 and 700 nm;

molar absorption coefficient is below the benchmark ($1000 \text{ L mol}^{-1} \cdot \text{cm}^{-1}$)

9. **Appearance/Organoleptic:** A clear liquid

3. Exposure

1. **Volume of Use (worldwide band):** < 0.1–1 metric ton per year (IFRA, 2015)
2. **95th Percentile Concentration in Hydroalcoholics:** 0.0011% (RIFM, 2016)
3. **Inhalation Exposure*:** 0.0000020 mg/kg/day or 0.00014 mg/day (RIFM, 2016)
4. **Total Systemic Exposure**:** 0.000076 mg/kg/day (RIFM, 2016)

*95th percentile calculated exposure derived from concentration survey data in the Creme RIFM Aggregate Exposure Model (Comiskey et al., 2015; Safford et al., 2015a; Safford et al., 2017; and Comiskey et al., 2017).

**95th percentile calculated exposure; assumes 100% absorption unless modified by dermal absorption data as reported in Section IV. It is derived from concentration survey data in the Creme RIFM Aggregate Exposure Model and includes exposure via dermal, oral, and inhalation routes whenever the fragrance ingredient is used in products that include these routes of exposure (Comiskey et al., 2015; Safford et al., 2015a; Safford et al., 2017; and Comiskey et al., 2017).

4. Derivation of systemic absorption

1. **Dermal:** Assumed 100%
2. **Oral:** Assumed 100%
3. **Inhalation:** Assumed 100%

5. Computational toxicology evaluation

1. **Cramer Classification:** Class III, High

| Expert Judgment | Toxtree v 2.6 | OECD QSAR Toolbox v 3.2 |
|-----------------|---------------|-------------------------|
| III | III | III |

2. Analogs Selected:

- a. **Genotoxicity:** Octahydrocoumarin (CAS # 4430-31-3)
- b. **Repeated Dose Toxicity:** None
- c. **Reproductive Toxicity:** None
- d. **Skin Sensitization:** None
- e. **Phototoxicity/Photoallergenicity:** None
- f. **Local Respiratory Toxicity:** None
- g. **Environmental Toxicity:** None

3. **Read-across Justification:** See [Appendix](#) below

6. Metabolism

Not considered for this risk assessment and therefore not reviewed except where it may pertain in specific endpoint sections as discussed below.

7. Natural occurrence (discrete chemical) or composition (NCS)

Lactoscatone is not reported to occur in food by the VCF.*

*VCF Volatile Compounds in Food: Database/Nijssen, L.M.; Ingen-Visscher, C.A. van; Donders, J.J.H. (eds). – Version 15.1 – Zeist (The Netherlands): TNO Triskelion, 1963–2014. A continually updated database containing information on published volatile compounds that

have been found in natural (processed) food products. Includes FEMA GRAS and EU-Flavis data.

8. IFRA standard

None.

9. REACH dossier

Pre-registered for 11/30/2010; no dossier available as of 11/08/2018.

10. Summary

10.1. Human health endpoint summaries

10.1.1. Genotoxicity

Based on the current existing data and use levels, lactoscatone does not present a concern for genetic toxicity.

10.1.1.1. Risk assessment. Lactoscatone was assessed in the BlueScreen assay and found negative for both cytotoxicity (positive: < 80% relative cell density) and genotoxicity, with and without metabolic activation (RIFM, 2013b). BlueScreen is a screening assay that assesses genotoxic stress through alterations in gene expressions in a human cell line. Additional assays on a more reactive read-across material were considered to fully assess the potential mutagenic or clastogenic effects of the target material.

There are no studies assessing the mutagenicity of lactoscatone. The mutagenic activity of read-across material octahydrocoumarin (CAS # 4430-31-3) has been evaluated in a bacterial reverse mutation assay conducted in compliance with GLP regulations and in accordance with OECD TG 471 using the preincubation method. *Salmonella typhimurium* strains TA98, TA100, TA1535, TA1537, and *Escherichia coli* strain WP2uvrA were treated with octahydrocoumarin in dimethyl sulfoxide (DMSO) at concentrations up to 5000 µg/plate. No increases in the mean number of revertant colonies were observed at any tested concentration in the presence or absence of S9 (RIFM, 2013a). Under the conditions of the study, octahydrocoumarin was not mutagenic in the Ames test, and this can be extended to lactoscatone.

There are no studies assessing the clastogenicity of lactoscatone. The clastogenic activity of octahydrocoumarin was evaluated in an *in vitro* micronucleus test conducted in compliance with GLP regulations and in accordance with OECD TG 487. Human peripheral blood lymphocytes were treated with octahydrocoumarin in DMSO at concentrations up to 1540 µg/mL in the presence and absence of metabolic activation (S9) for 3 h and in the absence of metabolic activation for 24 h. Octahydrocoumarin did not induce binucleated cells with micronuclei when tested up to the maximum concentration in either the presence or absence of an S9 activation system (RIFM, 2014). Under the conditions of the study, octahydrocoumarin was considered to be non-clastogenic in the *in vitro* micronucleus test, and this can be extended to lactoscatone.

Based on the available data, lactoscatone does not present a concern for genotoxic potential.

Additional References: None.

Literature Search and Risk Assessment Completed On: 1/1/18.

10.1.2. Repeated dose toxicity

There are insufficient repeated dose toxicity data on lactoscatone or on any read-across materials. The total systemic exposure to lactoscatone is below the TTC for the repeated dose toxicity endpoint of a Cramer Class III material at the current level of use.

10.1.2.1. Risk assessment. There are no repeated dose toxicity data on lactoscatone or on any read-across materials that can be used to support

the repeated dose toxicity endpoint. The total systemic exposure to lactoscatone (0.076 µg/kg bw/day) is below the TTC (1.5 µg/kg bw/day; Kroes et al., 2007) for the repeated dose toxicity endpoint of a Cramer Class III material at the current level of use.

Additional References: None.

Literature Search and Risk Assessment Completed On: 12/18/17.

10.1.3. Reproductive Toxicity

There are insufficient reproductive toxicity data on lactoscatone or on any read-across materials. The total systemic exposure to lactoscatone is below the TTC for the reproductive toxicity endpoint of a Cramer Class III material at the current level of use.

10.1.3.1. Risk assessment. There are no reproductive toxicity data on lactoscatone or on any read-across materials that can be used to support the reproductive toxicity endpoint. The total systemic exposure to lactoscatone (0.076 µg/kg bw/day) is below the TTC (1.5 µg/kg bw/day; Kroes et al., 2007; Laufersweiler et al., 2012) for the reproductive toxicity endpoint of a Cramer Class III material at the current level of use.

Additional References: None.

Literature Search and Risk Assessment Completed On: 12/18/17.

10.1.4. Skin sensitization

Based on the existing data, lactoscatone does not present a concern for skin sensitization.

10.1.4.1. Risk assessment. The chemical structure of this material indicates that it would not be expected to react with skin proteins (Toxtree 2.6.13; OECD toolbox v4.1). No predictive skin sensitization studies are available for lactoscatone or read-across materials. However, in a human maximization test, no skin sensitization reactions were observed (RIFM, 1980).

Acting conservatively, due to the limited data, the reported exposure was benchmarked utilizing the non-reactive Dermal Sensitization Threshold (DST) of 900 µg/cm² (Roberts et al., 2015; Safford, 2008; Safford et al., 2011; Safford et al., 2015b). The current exposure from the 95th percentile concentration is below the DST for non-reactive materials when evaluated in all QRA categories. Table 1 provides the maximum acceptable concentrations for lactoscatone that present no appreciable risk for skin sensitization based on the non-

reactive DST. These concentrations are not limits; they represent maximum acceptable concentrations based on the DST approach.

Additional References: None.

Literature Search and Risk Assessment Completed On: 01/02/17.

10.1.5. Phototoxicity/photoallergenicity

Based on the available UV/Vis spectra, lactoscatone would not be expected to present a concern for phototoxicity or photoallergenicity.

10.1.5.1. Risk assessment. There are no phototoxicity studies available for lactoscatone in experimental models. UV/Vis absorption spectra indicate no significant absorption between 290 and 700 nm. The corresponding molar absorption coefficient is well below the benchmark of concern for phototoxicity and photoallergenicity (Henry et al., 2009). Based on lack of absorbance, lactoscatone does not present a concern for phototoxicity or photoallergenicity.

10.1.5.2. UV spectra analysis. UV/Vis absorption spectra (OECD TG 101) were obtained. The spectra indicate no significant absorbance in the range of 290–700 nm. The molar absorption coefficient is below the benchmark of concern for phototoxic effects, 1000 L mol⁻¹ · cm⁻¹ (Henry et al., 2009).

Additional References: None.

Literature Search and Risk Assessment Completed On: 11/01/16.

10.1.6. Local Respiratory Toxicity

The margin of exposure could not be calculated due to lack of appropriate data. The exposure level for lactoscatone is below the Cramer Class III TTC value for inhalation exposure local effects.

10.1.6.1. Risk assessment. There are no inhalation data available on lactoscatone. Based on the Creme RIFM Model, the inhalation exposure is 0.00014 mg/day. This exposure is 3357 times lower than the Cramer Class III TTC value of 0.47 mg/day (based on human lung weight of 650 g; Carthew et al., 2009); therefore, the exposure at the current level of use is deemed safe.

Additional References: None.

Literature Search and Risk Assessment Completed On: 01/05/17.

Table 1

Maximum acceptable concentrations for lactoscatone that present no appreciable risk for skin sensitization based on non-reactive DST.

| IFRA Category ^a | Description of Product Type | Maximum Acceptable Concentrations in Finished Products Based on Non-reactive DST | Reported 95th Percentile Concentration in Finished Products |
|----------------------------|--|--|---|
| 1 | Products applied to the lips | 0.07% | 0.00% ^b |
| 2 | Products applied to the axillae | 0.02% | 0.00% ^b |
| 3 | Products applied to the face using fingertips | 0.41% | 0.00% ^b |
| 4 | Fine fragrance products | 0.39% | 0.00% ^b |
| 5 | Products applied to the face and body using the hands (palms), primarily leave-on | 0.10% | 0.00% ^b |
| 6 | Products with oral and lip exposure | 0.23% | 0.00% |
| 7 | Products applied to the hair with some hand contact | 0.79% | 0.00% ^b |
| 8 | Products with significant ano-genital exposure | 0.04% | No Data ^c |
| 9 | Products with body and hand exposure, primarily rinse-off | 0.75% | 0.00% ^b |
| 10 | Household care products with mostly hand contact | 2.70% | 0.00% ^b |
| 11 | Products with intended skin contact but minimal transfer of fragrance to skin from inert substrate | 1.50% | No Data ^c |
| 12 | Products not intended for direct skin contact, minimal or insignificant transfer to skin | Not Restricted | 0.04% |

Note:

^a For a description of the categories, refer to the IFRA/RIFM Information Booklet.

^b Negligible exposure (< 0.01%).

^c Fragrance exposure from these products is very low. These products are not currently in the Creme RIFM Aggregate Exposure Model.

10.2. Environmental endpoint summary

10.2.1. Screening-level assessment

A screening-level risk assessment of lactoscatone was performed following the RIFM Environmental Framework (Salvito et al., 2002), which provides 3 tiered levels of screening for aquatic risk. In Tier 1, only the material's regional VoU, its log K_{OW} , and its molecular weight are needed to estimate a conservative risk quotient (RQ), expressed as the ratio Predicted Environmental Concentration/Predicted No Effect Concentration (PEC/PNEC). A general QSAR with a high uncertainty factor applied is used to predict fish toxicity, as discussed in Salvito et al. (2002). In Tier 2, the RQ is refined by applying a lower uncertainty factor to the PNEC using the ECOSAR model (US EPA, 2012b), which provides chemical class-specific ecotoxicity estimates. Finally, if necessary, Tier 3 is conducted using measured biodegradation and ecotoxicity data to refine the RQ, thus allowing for lower PNEC uncertainty factors. The data for calculating the PEC and PNEC for this safety assessment are provided in the table below. For the PEC, the range from the most recent IFRA Volume of Use Survey is reviewed. The PEC is then calculated using the actual regional tonnage, not the extremes of the range. Following the RIFM Environmental Framework, lactoscatone was identified as a fragrance material with no potential to present a possible risk to the aquatic environment (i.e., its screening-level PEC/PNEC < 1).

A screening-level hazard assessment using EPI Suite v4.1 (US EPA, 2012a) identified lactoscatone as possibly persistent but not bioaccumulative based on its structure and physical-chemical properties. This screening-level hazard assessment considers the potential for a material to be persistent and bioaccumulative and toxic, or very persistent and very bioaccumulative as defined in the Criteria Document (Api et al., 2015). As noted in the Criteria Document, the screening criteria applied are the same as those used in the EU for REACH (ECHA, 2012). For persistence, if the EPI Suite model BIOWIN 3 predicts a value < 2.2 and either BIOWIN 2 or BIOWIN 6 predicts a value < 0.5, then the material is considered potentially persistent. A material would be considered potentially bioaccumulative if the EPI Suite model BCFBAF predicts a fish BCF ≥ 2000 L/kg. Ecotoxicity is determined in the above screening-level risk assessment. If, based on these model outputs (Step 1), additional assessment is required, a WoE-based review is then performed (Step 2). This review considers available data on the material's physical-chemical properties, environmental fate (e.g., OECD Guideline biodegradation studies or die-away studies), fish bioaccumulation, and higher-tier model outputs (e.g., US EPA's BIOWIN and BCFBAF found in EPI Suite v4.1). Data on persistence and bioaccumulation are reported below and summarized in the Environmental Safety Assessment section prior to Section 1.

10.2.2. Risk assessment

Based on current Volume of Use (2015), lactoscatone does not present a risk to the aquatic compartment in the screening-level assessment.

10.2.3. Key studies

10.2.3.1. Biodegradation. RIFM, 1996: The biodegradability of the test material was evaluated using the biochemical oxygen demand (BOD) test for insoluble substances (BODIS). The extent of biodegradation was calculated as the cumulative BOD related to the theoretical oxygen demand. Biodegradation of 9.4% was observed after 28 days.

10.2.3.2. Ecotoxicity. RIFM, 2000: A *Daphnia magna* immobilization test was conducted according to the OECD 202 I method under static conditions. The 48-h EC50 was reported to be 23 mg/L.

10.2.3.3. Other available data. Lactoscatone has been pre-registered for REACH with no additional data at this time.

10.2.4. Risk assessment refinement

Since lactoscatone has passed the screening criteria, measured data is included for completeness only and has not been used in PNEC derivation.

Ecotoxicological data and PNEC derivation (all endpoints reported in mg/L; PNECs in $\mu\text{g/L}$).

Endpoints used to calculate PNEC are underlined.

| | LC50 (Fish) (mg/L) | EC50 (<i>Daphnia</i>) (mg/L) | EC50 (Algae) (mg/L) | AF | PNEC ($\mu\text{g/L}$) | Chemical Class |
|---|--------------------------|--------------------------------------|------------------------|-----------|--------------------------|----------------|
| RIFM Framework Screening-level (Tier 1) | <u>22.62</u> | | | 1,000,000 | 0.02262 | |

Exposure information and PEC calculation (following RIFM Environmental Framework: Salvito et al., 2002).

| Exposure | Europe (EU) | North America (NA) |
|--|---------------|--------------------|
| Log K_{OW} used | 3.2 | 3.2 |
| Biodegradation Factor Used | 0 | 0 |
| Dilution Factor | 3 | 3 |
| Regional Volume of Use Tonnage Band | < 1 | < 1 |
| Risk Characterization: PEC/PNEC | < 1 | < 1 |

Based on available data, the RQ for this material is < 1. No additional assessment is necessary.

The RIFM PNEC is 0.02262 $\mu\text{g/L}$. The revised PEC/PNECs for EU and NA are: not applicable. The material was cleared at the screening-level and therefore does not present a risk to the aquatic environment at the current reported volumes of use.

Literature Search and Risk Assessment Completed On: 1/3/18.

11. Literature Search*

- **RIFM Database:** Target, Fragrance Structure Activity Group materials, other references, JECFA, CIR, SIDS
- **ECHA:** <http://echa.europa.eu/>
- **NTP:** <https://ntp.niehs.nih.gov/>
- **OECD Toolbox**
- **SciFinder:** <https://scifinder.cas.org/scifinder/view/scifinder/scifinderExplore.jsf>
- **PubMed:** <http://www.ncbi.nlm.nih.gov/pubmed>
- **TOXNET:** <http://toxnet.nlm.nih.gov/>
- **IARC:** <http://monographs.iarc.fr>
- **OECD SIDS:** <http://webnet.oecd.org/hpv/ui/Default.aspx>
- **EPA ACToR:** <https://actor.epa.gov/actor/home.xhtml>
- **US EPA HPVIS:** https://ofmpub.epa.gov/opthpv/public_search_publicdetails?submission_id=24959241&ShowComments=Yes&sqlstr=null&recordcount=0&User_title=DetailQuery%20Results&EndPointRpt=Y#submission
- **Japanese NITE:** <http://www.safe.nite.go.jp/english/db.html>
- **Japan Existing Chemical Data Base (JECDB):** http://dra4.nihs.go.jp/mhlw_data/jsp/SearchPageENG.jsp
- **Google:** <https://www.google.com>
- **ChemIDplus:** <https://chem.nlm.nih.gov/chemidplus/>

Search keywords: CAS number and/or material names.

*Information sources outside of RIFM's database are noted as appropriate in the safety assessment. This is not an exhaustive list. The links listed above were active as of 10/09/2018.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.fct.2019.01.022>.



Appendix

Read-across Justification

Methods

The read-across analogs were identified following the strategy for structuring and reporting a read-across prediction of toxicity described in Schultz et al. (2015). The strategy is also consistent with the guidance provided by OECD within Integrated Approaches for Testing and Assessment (OECD, 2015) and the European Chemicals Agency read-across assessment framework (ECHA, 2016).

- First, materials were clustered based on their structural similarity. Second, data availability and data quality on the selected cluster were examined. Third, appropriate read-across analogs from the cluster were confirmed by expert judgment.
- Tanimoto structure similarity scores were calculated using FCFC4 fingerprints (Rogers and Hahn, 2010).
- The physical–chemical properties of the target substance and the read-across analogs were calculated using EPI Suite v4.11 (US EPA, 2012a).
- J_{\max} values were calculated using RIFM's skin absorption model (SAM). The parameters were calculated using the consensus model (Shen et al., 2014).
- DNA binding, mutagenicity, genotoxicity alerts, and oncologic classification predictions were generated using OECD QSAR Toolbox v3.4 (OECD, 2018).
- ER binding and repeat dose categorization were generated using OECD QSAR Toolbox v3.4 (OECD, 2018).
- Developmental toxicity was predicted using CAESAR v2.1.7 (Cassano et al., 2010), and skin sensitization was predicted using Toxtree 2.6.13.
- Protein binding was predicted using OECD QSAR Toolbox v3.4 (OECD, 2018).
- The major metabolites for the target and read-across analogs were determined and evaluated using OECD QSAR Toolbox v3.4 (OECD, 2018).

| | Target Material | Read-across Material |
|--|--|---|
| Principal Name | Lactoscatone | Octahydrocoumarin |
| CAS No. | 21280-29-5 | 4430-31-3 |
| Structure |  |  |
| Similarity (Tanimoto Score) | | 0.5 |
| Read-across Endpoint | | • Genotoxicity |
| Molecular Formula | $C_{14}H_{22}O_2$ | $C_9H_{14}O_2$ |
| Molecular Weight | 222.33 | 154.21 |
| Melting Point (°C, EPI Suite) | 93.27 | 16.99 |
| Boiling Point (°C, EPI Suite) | 319.12 | 271.33 |
| Vapor Pressure (Pa @ 25 °C, EPI Suite) | 0.0205 | 1.14 |
| Log K_{OW} (KOWWIN v1.68 in EPI Suite) | 3.29 | 1.55 |
| Water Solubility (mg/L, @ 25 °C, WSKOW v1.42 in EPI Suite) | 51.92 | 3462 |
| J_{\max} (mg/cm ² /h, SAM) | 1.43 | 33.098 |
| Henry's Law (Pa·m ³ /mol, Bond Method, EPI Suite) | 3.39E-004 | 1.87E-004 |
| Genotoxicity | | |
| DNA Binding (OASIS v1.4, QSAR Toolbox v3.4) | • No alert found | • No alert found |
| DNA Binding (OECD QSAR Toolbox v3.4) | • No alert found | • No alert found |
| Carcinogenicity (ISS) | • No alert found | • No alert found |
| DNA Binding (Ames, MN, CA, OASIS v1.1) | • No alert found | • No alert found |
| <i>In Vitro</i> Mutagenicity (Ames, ISS) | • No alert found | • No alert found |
| <i>In Vivo</i> Mutagenicity (Micronucleus, ISS) | • No alert found | • No alert found |
| Oncologic Classification | • Lactone type reactive functional groups | • Lactone type reactive functional groups |
| Metabolism | | |
| Rat Liver S9 Metabolism Simulator and Structural Alerts for Metabolites (OECD QSAR Toolbox v3.4) | See Supplemental Data 1 | See Supplemental Data 2 |

Summary

There are insufficient toxicity data on lactoscatone (CAS # 21280-29-5). Hence, *in silico* evaluation was conducted to determine read-across analogs for this material. Based on structural similarity, reactivity, physical–chemical properties, and expert judgment, octahydrocoumarin (CAS 4430-31-3) was identified as a read-across material with sufficient data for toxicological evaluation.

Conclusions

- Octahydrocoumarin (CAS # 4430-31-3) was used as a read-across analog for the target material lactoscatone (CAS # 21280-29-5) for the genotoxicity endpoint.
 - The target substance and the read-across analog are structurally similar and belong to the class of lactones.
 - The target substance and the read-across analog share an octahydrocoumarin structure.
 - The key difference between the target substance and the read-across analog is that the target substance has a methyl substitution and a bridged structure on the octahydrocoumarin scaffold. This structural difference is toxicologically insignificant.
 - Similarity between the target substance and the read-across analog is indicated by the Tanimoto score. The Tanimoto score is mainly driven by the octahydrocoumarin structure. Differences between the structures that affect the Tanimoto score are toxicologically insignificant.
 - The physical–chemical properties of the target substance and the read-across analog are sufficiently similar to enable comparison of their toxicological properties.
 - Differences are predicted for J_{\max} , which estimates skin absorption. J_{\max} for the target substance corresponds to skin absorption $\leq 40\%$, and J_{\max} for the read-across analog corresponds to skin absorption $\leq 80\%$. While percentage skin absorption estimated from J_{\max} indicates exposure to the substance, it does not represent hazard or toxicity. This parameter provides context to assess the impact of bioavailability on toxicity comparisons between the materials evaluated.
 - According to the OECD QSAR Toolbox v3.4, structural alerts for toxicological endpoints are consistent between the target substance and the read-across analog.
 - Both the target substance and the read-across analog are classified as lactone functional groups under oncologic primary classification by the OECD QSAR Toolbox. This is due to the fact that lactones are cyclic esters that may open to serve as acylating agents. In general, the ability to open the ring is dependent on the size of the ring. The smallest lactone is the strained 4-membered ring (β -lactone) that can open easily and spontaneously. The ability to open the ring decreases with increase in the size of the lactone ring. The carcinogenicity potential of lactones roughly correlates with their ability to serve as acylating agents. All other genotoxicity alerts are negative. The data described in the genotoxicity section show that the read-across analog does not pose a concern for genetic toxicity under the current level of use. Based on the structural similarity between the target substance and the read-across analog and the data for the read-across analog, the alerts are superseded by the data.
 - The target substance and the read-across analog are expected to be metabolized similarly, as shown by the metabolism simulator.
 - The structural alerts for the endpoints evaluated are consistent between the metabolites of the read-across analog and the target material.

References

- Api, A.M., Belsito, D., Bruze, M., Cadby, P., Calow, P., Dagli, M.L., Dekant, W., Ellis, G., Fryer, A.D., Fukayama, M., Griem, P., Hickey, C., Kromidas, L., Lalko, J.F., Liebler, D.C., Miyachi, Y., Politano, V.T., Renskers, K., Ritacco, G., Salvito, D., Schultz, T.W., Sipes, I.G., Smith, B., Vitale, D., Wilcox, D.K., 2015. Criteria for the research Institute for fragrance materials, Inc. (RIFM) safety evaluation process for fragrance ingredients. *Food Chem. Toxicol.* 82, S1–S19.
- Carthew, P., Clapp, C., Gutsell, S., 2009. Exposure based waiving: the application of the toxicological threshold of concern (TTC) to inhalation exposure for aerosol ingredients in consumer products. *Food Chem. Toxicol.* 47 (6), 1287–1295.
- Cassano, A., Manganaro, A., Martin, T., Young, D., Piclin, N., Pintore, M., Bigoni, D., Benfenati, E., 2010. CAESAR models for developmental toxicity. *Chem. Cent. J.* 4 (Suppl. 1), S4.
- Comiskey, D., Api, A.M., Barratt, C., Daly, E.J., Ellis, G., McNamara, C., O'Mahony, C., Robison, S.H., Safford, B., Smith, B., Tozer, S., 2015. Novel database for exposure to fragrance ingredients in cosmetics and personal care products. *Regul. Toxicol. Pharmacol.* 72 (3), 660–672.
- Comiskey, D., Api, A.M., Barrett, C., Ellis, G., McNamara, C., O'Mahony, C., Robison, S.H., Rose, J., Safford, B., Smith, B., Tozer, S., 2017. Integrating habits and practices data for soaps, cosmetics and air care products into an existing aggregate exposure model. *Regul. Toxicol. Pharmacol.* 88, 144–156.
- ECHA, 2012. Guidance on Information Requirements and Chemical Safety Assessment Chapter R.11: PBT Assessment, November 2012 v1.1. <http://echa.europa.eu/>.
- ECHA, 2016. Read-across Assessment Framework (RAAF). Retrieved from. www.echa.europa.eu/documents/10162/13628/raaf_en.pdf.
- Henry, B., Foti, C., Alsante, K., 2009. Can light absorption and photostability data be used to assess the photosafety risks in patients for a new drug molecule? *J. Photochem. Photobiol. B Biol.* 96 (1), 57–62.
- IFRA (International Fragrance Association), 2015. Volume of Use Survey, February 2015.
- Kroes, R., Renwick, A.G., Feron, V., Galli, C.L., Gibney, M., Greim, H., Guy, R.H., Lhuguenot, J.C., van de Sandt, J.J.M., 2007. Application of the threshold of toxicological concern (TTC) to the safety evaluation of cosmetic ingredients. *Food Chem. Toxicol.* 45 (12), 2533–2562.
- Laufersweiler, M.C., Gadagbui, B., Baskerville-Abraham, I.M., Maier, A., Willis, A., et al., 2012. Correlation of chemical structure with reproductive and developmental toxicity as it relates to the use of the threshold of toxicological concern. *Regul. Toxicol. Pharmacol.* 62 (1), 160–182.
- OECD, 2015. Guidance Document on the Reporting of Integrated Approaches to Testing and Assessment (IATA). ENV/JM/HA(2015)7. Retrieved from. <http://www.oecd.org/>.
- OECD, 2018. The OECD QSAR Toolbox, v3.2–4.2. Retrieved from. <http://www.qsartoolbox.org/>.
- RIFM (Research Institute for Fragrance Materials, Inc.), 1980. Report on Human Maximization Studies. Report to RIFM. RIFM report number 1790. RIFM, Woodcliff Lake, NJ, USA.
- RIFM (Research Institute for Fragrance Materials, Inc.), 1996. Assessment of the Biodegradability of Lactoscatone with the BOD Test for Insoluble Substances (BODIS). Unpublished report from Symrise. RIFM report number 61611. RIFM, Woodcliff Lake, NJ, USA.
- RIFM (Research Institute for Fragrance Materials, Inc.), 2000. Acute Immobilisation Test (48 H) of Lactoscatone to Daphnia Magna STRAUS. Unpublished report from Dragoco Gerberding and Co. GmbH. RIFM report number 37776. RIFM, Woodcliff Lake, NJ, USA.
- RIFM (Research Institute for Fragrance Materials, Inc.), 2013a. Octahydrocoumarin: Reverse Mutation Assay "Ames Test" Using Salmonella typhimurium and Escherichia coli. RIFM report number 65015. RIFM, Woodcliff Lake, NJ, USA.
- RIFM (Research Institute for Fragrance Materials, Inc.), 2013b. Report on the Testing of Lactoscatone in the BlueScreen HC Assay (-/+ S9 Metabolic Activation). RIFM report number 66082. RIFM, Woodcliff Lake, NJ, USA.
- RIFM (Research Institute for Fragrance Materials, Inc.), 2014. Octahydrocoumarin: in Vitro Mammalian Cell Micronucleus Assay in Human Peripheral Blood Lymphocytes (HPBL). RIFM report number 66712. RIFM, Woodcliff Lake, NJ, USA.
- RIFM (Research Institute for Fragrance Materials, Inc.), 2016. Exposure Survey 10, March 2016.
- Roberts, D.W., Api, A.M., Safford, R.J., Lalko, J.F., 2015. Principles for identification of high potency category chemicals for which the dermal sensitization threshold (DST) approach should not be applied. *Regul. Toxicol. Pharmacol.* 72 (3), 683–693.
- Rogers, D., Hahn, M., 2010. Extended-connectivity fingerprints. *J. Chem. Inf. Model.* 50 (5), 742–754.
- Safford, B., Api, A.M., Barratt, C., Comiskey, D., Daly, E.J., Ellis, G., McNamara, C., O'Mahony, C., Robison, S., Smith, B., Thomas, R., Tozer, S., 2015a. Use of an aggregate exposure model to estimate consumer exposure to fragrance ingredients in personal care and cosmetic products. *Regul. Toxicol. Pharmacol.* 72, 673–682.
- Safford, B., Api, A.M., Barratt, C., Comiskey, D., Ellis, G., McNamara, C., O'Mahony, C., Robison, S., Rose, J., Smith, B., Tozer, S., 2017. Application of the expanded Creme RIFM consumer exposure model to fragrance ingredients in cosmetic, personal care and air care products. *Regul. Toxicol. Pharmacol.* 86, 148–156.
- Safford, R.J., 2008. The dermal sensitisation threshold—A TTC approach for allergic contact dermatitis. *Regul. Toxicol. Pharmacol.* 51 (2), 195–200.
- Safford, R.J., Api, A.M., Roberts, D.W., Lalko, J.F., 2015b. Extension of the dermal sensitization threshold (DST) approach to incorporate chemicals classified as reactive. *Regul. Toxicol. Pharmacol.* 72 (3), 694–701.
- Safford, R.J., Aptula, A.O., Gilmour, N., 2011. Refinement of the dermal sensitisation threshold (DST) approach using a larger dataset and incorporating mechanistic chemistry domains. *Regul. Toxicol. Pharmacol.* 60 (2), 218–224.
- Salvito, D.T., Senna, R.J., Federle, T.W., 2002. A Framework for prioritizing fragrance

- materials for aquatic risk assessment. *Environ. Toxicol. Chem.* 21 (6), 1301–1308.
- Schultz, T.W., Amcoff, P., Berggren, E., Gautier, F., Klaric, M., Knight, D.J., Mahony, C., Schwarz, M., White, A., Cronin, M.T., 2015. A strategy for structuring and reporting a read-across prediction of toxicity. *Regul. Toxicol. Pharmacol.* 72 (3), 586–601.
- Shen, J., Kromidas, L., Schultz, T., Bhatia, S., 2014. An *in silico* skin absorption model for fragrance materials. *Food Chem. Toxicol.* 74, 164–176.
- US EPA, 2012a. Estimation Programs Interface Suite for Microsoft Windows, v4.0–v4.11. United States Environmental Protection Agency, Washington, DC, USA.
- US EPA, 2012b. The ECOSAR (ECOLOGICAL Structure Activity Relationship) Class Program for Microsoft Windows, v1.11. United States Environmental Protection Agency, Washington, DC, USA.